author-photo

Jean Francois Martini

Pfizer

63

Papers

2178

Citations

Citation Trend

Filter By

Papers (45) Sort By

Journal Conference Others

Transcriptomics in Tumor and Normal Tissues and Precision Oncology Algorithms Identify Early-Stage NSCLC Patients with High Risk of Post-Surgery Recurrence Who May Benefit from Adjuvant Therapies

2021 Social Science Research Network
Show All
- Source
- Cite
- Save
Citations (0)
Early circulating tumor (ct) DNA dynamics and efficacy of lorlatinib: Analysis from the CROWN study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract LB043: Efficacy of Lorlatinib in Treatment-Naïve Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT025: Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC)

2020 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT135: A phase 1b study of palbociclib + nab-paclitaxel in patients (pts) with metastatic adenocarcinoma of the pancreas (PDAC)

2020 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (1)
Angiogenic and immune-related biomarkers and outcomes following axitinib/pembrolizumab treatment in patients with advanced renal cell carcinoma.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-Free Survival in Post-Nephrectomy High-Risk Loco-Regional RCC: Analysis of the S-TRAC Trial.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma.

2020 Future Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.

2020 Future Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)